Application 203611
- Type
- ANDA
- Sponsor
- ACTAVIS ELIZABETH
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | GABAPENTIN | GABAPENTIN | TABLET; ORAL | 300MG | No | No |
| 002 | GABAPENTIN | GABAPENTIN | TABLET; ORAL | 600MG | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A203611-001 | GABAPENTIN | GABAPENTIN | 300MG | TABLET / ORAL | AB2 | 2026-06-23 | |
| A203611-002 | GABAPENTIN | GABAPENTIN | 600MG | TABLET / ORAL | AB2 | 2026-06-23 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A203611-001 | AB2 |
| A203611-002 | AB2 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A203611-001 | GABAPENTIN | 300MG | TABLET / ORAL | AB2 | 2026-06-23 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A203611-002 | GABAPENTIN | 600MG | TABLET / ORAL | AB2 | 2026-06-23 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A203611-001 | GABAPENTIN | 300MG | TABLET / ORAL | AB2 | 2026-06-23 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A203611-002 | GABAPENTIN | 600MG | TABLET / ORAL | AB2 | 2026-06-23 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A203611-001 | GABAPENTIN | 300MG | TABLET / ORAL | AB2 | 2026-06-23 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A203611-002 | GABAPENTIN | 600MG | TABLET / ORAL | AB2 | 2026-06-23 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A203611-001 | GABAPENTIN | 300MG | TABLET / ORAL | AB2 | 2026-06-23 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A203611-002 | GABAPENTIN | 600MG | TABLET / ORAL | AB2 | 2026-06-23 | caaa826d4ba7… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A203611-001 | GABAPENTIN | 300MG | TABLET / ORAL | AB2 | 2026-06-23 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A203611-002 | GABAPENTIN | 600MG | TABLET / ORAL | AB2 | 2026-06-23 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A203611-001 | AB2 | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A203611-002 | AB2 | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A203611-001 | AB2 | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A203611-002 | AB2 | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A203611-001 | AB2 | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A203611-002 | AB2 | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A203611-001 | AB2 | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A203611-002 | AB2 | 1 | caaa826d4ba7… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A203611-001 | AB2 | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A203611-002 | AB2 | 1 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Gabapentin | GABAPENTIN | HAWAII REPACK, INC. | dd7adad2-e2f5-4b43-90a4-522bce0be5b3 | 2026-11-09 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| GABAPENTIN | GABAPENTIN | Havix Group Inc d-b-a Aavis Pharmaceuticals | ad6c10e6-fc39-4ca2-942f-a56c4457e144 | 2026-11-06 | GABAPENTIN GABAPENTIN | |
| Gabapentin | GABAPENTIN | REMEDYREPACK INC. | 4615aaa7-73d4-4473-8f26-e7a982f8a166 | 2026-11-05 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Bryant Ranch Prepack | 4c49d34d-bb47-406b-8f2d-b4834b2ee9d0 | 2026-11-04 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| GABAPENTIN | GABAPENTIN | Bryant Ranch Prepack | c33c4d83-cc13-4104-9e24-d4cd40b17b70 | 2026-10-30 | Warnings, Adverse reactions | GABAPENTIN GABAPENTIN |
| GABAPENTIN | GABAPENTIN | Bryant Ranch Prepack | 5769d849-4f27-4701-97ec-7e3ca07339d7 | 2026-10-30 | Warnings, Adverse reactions | GABAPENTIN GABAPENTIN |
| Gabapentin | GABAPENTIN | Bryant Ranch Prepack | a1006139-7dfc-4d87-a5a9-aeb380c32d24 | 2026-10-30 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| GABAPENTIN | GABAPENTIN | Bryant Ranch Prepack | e2d9bd8c-3bb9-4945-8e61-7d2703d9008c | 2026-10-30 | Warnings, Adverse reactions | GABAPENTIN GABAPENTIN |
| Gabapentin | GABAPENTIN | REMEDYREPACK INC. | fb726cb0-d422-48dd-a8ed-adbde812b005 | 2026-10-29 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Bryant Ranch Prepack | d8604417-9d43-4d27-a7ce-d4120ff201f4 | 2026-10-28 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | REMEDYREPACK INC. | 7f830664-2fa3-4d73-a154-775fbb8fd65d | 2026-10-28 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Bryant Ranch Prepack | 6a0a75ac-e121-477b-a9d1-d11f588afc9d | 2026-10-28 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| GABAPENTIN | GABAPENTIN | Bryant Ranch Prepack | 78088f6a-06a3-422f-b336-4a57a24adc16 | 2026-10-27 | Warnings, Adverse reactions | GABAPENTIN GABAPENTIN |
| Gabapentin | GABAPENTIN | ScieGen Pharmaceuticals, Inc. | 5ab9c18b-9568-4dcb-90b0-252aef8f8dc2 | 2026-10-23 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Ascend Laboratories, LLC | 4d445d1d-02d1-4a59-b3b2-9ba5cd924c9a | 2026-10-23 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Northwind Health Company, LLC | 552912b2-be59-0333-e063-6394a90a85c0 | 2026-10-19 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | St. Mary's Medical Park Pharmacy | 5de61c1f-8e6f-b70a-e063-6294a90a1c21 | 2026-10-15 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | PD-Rx Pharmaceuticals, Inc. | b4c7388a-19d9-4e3a-83c9-4943fb855be4 | 2026-10-14 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | REMEDYREPACK INC. | e877a425-2b7f-4e43-a1f9-24019cbf9685 | 2026-10-09 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
| Gabapentin | GABAPENTIN | Granules Pharmaceuticals Inc. | e847bcfa-f3de-404a-8a57-d8a414691e6a | 2026-10-08 | Warnings, Adverse reactions | Gabapentin GABAPENTIN |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.